Related Experiment Videos
Aromatase inhibitors: their biochemistry and clinical potential
1Research Laboratories of Schering AG, Berlin, Federal Republic of Germany.
Abstract:
It has been proposed that one of the endocrinological factors in the pathogenesis of benign prostatic hyperplasia is estrogen stimulation of stromal growth. Current clinical experience with anti-estrogenic compounds indicates that, in the case of mammary carcinoma, aromatase inhibitors provide a viable alternative to estrogen receptor antagonists for treatment of the disease. It is proposed that inhibitors of estrogen biosynthesis could likewise provide a non-invasive therapy for benign prostate disease. Some aspects of the activity of known aromatase inhibitors as substrates for enzymes of steroid metabolism and their potential relevance to the pharmacology of the compounds are discussed.
Insights
Aromatase inhibitors may offer a new, non-invasive treatment for benign prostatic hyperplasia (BPH) by blocking estrogen production, similar to their use in breast cancer therapy.
Area of Science:
- Endocrinology
- Urology
- Pharmacology
Background:
- Benign prostatic hyperplasia (BPH) pathogenesis may involve estrogen-driven stromal growth.
- Aromatase inhibitors are effective alternatives to estrogen receptor antagonists for breast cancer.
- Estrogen biosynthesis inhibitors could offer a novel therapeutic approach for BPH.
Purpose of the Study:
- To explore the potential of aromatase inhibitors as a non-invasive therapy for benign prostate disease.
- To discuss the role of estrogen in BPH pathogenesis.
- To review the pharmacology of aromatase inhibitors in steroid metabolism.
Main Methods:
- Review of current clinical experience with anti-estrogenic compounds.
- Discussion of the proposed mechanism of estrogen in BPH.
- Analysis of aromatase inhibitor activity as substrates for steroid metabolism enzymes.
Main Results:
- Aromatase inhibitors show promise as an alternative to estrogen receptor antagonists.
- Estrogen biosynthesis inhibition is proposed as a potential non-invasive therapy for BPH.
- Understanding enzyme interactions is crucial for aromatase inhibitor pharmacology.
Conclusions:
- Inhibitors of estrogen biosynthesis represent a potential non-invasive therapeutic strategy for BPH.
- Further research into aromatase inhibitors' interaction with steroid metabolism is warranted.
- Estrogen's role in BPH pathogenesis suggests a target for pharmacological intervention.